AzTrials
AzTrials

BlindnessNCT03002597

Visual Information Restoration and Rehabilitation Via Sensory Substitution Technology in Children

A study testing BrainPort V200 Device in people with Blindness, run by Ellen Mitchell at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The BrainPort vision device is a visual prosthetic designed for those who are blind. It enables perception of visual information using the tongue and camera system as a paired substitute for the eye. Read more about this study

Who is it for?
Ages 4 to 17 yearsHealthy volunteers can take part
Conditions the study is for
Blindness
What is being tested?
BrainPort V200 Device
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
9 participants
Where
1 siteUnited States
Study dates
Jan 2014to Jun 2021
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 4 to 17 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • Blind Children:
  • Between the age of 4 and 17.
  • Blind (documented visual acuity of light perception or worse) in both eyes from an eye care provider.
  • Able to understand and sign the Informed Consent and Assent form.
  • Able to understand the training and rehabilitation protocols involved in the study.
  • Willing to use the BrainPort device.
Show all 14Show fewer
  • Able to undergo functional neuroimaging tests
  • Sighted Children:
  • Between the age of 4 and 17.
  • Sighted in both eyes from an eye care provider.
  • Able to understand and sign the Informed Consent and Assent form.
  • Able to understand the training and rehabilitation protocols involved in the study.
  • Willing to use the BrainPort device.
  • Able to undergo functional neuroimaging tests

Who cannot join

  • Blind Children:
  • Current oral health problems as determined by the subject's history, and an examination of the oral cavity performed by a member of the study team. Subject is excluded if any of the following conditions are met:
  • A history of injury to the tongue resulting in impaired sensation or use of the tongue.
  • Visible open lesions, cold sores, abrasions, blisters, or rash on the tongue.
  • Oral surgery or dental work in the past 3 months or anticipated to occur for the duration of participation in the study (does not include routine dental health exams/cleanings).
  • Piercing on the tongue.
Show all 37Show fewer
  • Performance better than 20/5000 on the FrACT acuity test (same visual criteria as FDA safety study).
  • Known neuropathies of tongue or skin tactile system.
  • Unwilling or unable to adhere to all study requirements, including completion of the training period, evaluation tests and follow up visits.
  • Implanted electrical medical devices such as pacemakers.
  • Known allergies to nickel, gold or other components of stainless steel.
  • Patients who are 18 years and older or younger than 4.
  • Women who are pregnant or breast feeding will not be able to participate in this study (as indicated by a positive pregnancy test).
  • Children with neurodevelopmental disorders (e.g., autism, learning disabilities) or congenital brain malformations will be excluded from participation.
  • Cortical blindness from any cause.
  • Claustrophobia that would prevent functional neuroimaging (for those subjects undergoing neuroimaging only).
  • Obesity preventing placement in MRI scanner (for those subjects undergoing neuroimaging only).
  • Presence of any foreign metal in the body with the exception of dental fillings.
  • Implanted metallic or ferromagnetic objects (aneurysm clip, ear implant, IUD, shrapnel or metallic fragments in or on the body or eyes, neuro-stimulators, or other metal devices).
  • Sighted Children:
  • Current oral health problems as determined by the subject's history, and an examination of the oral cavity performed by a member of the study team. Subject is excluded if any of the following conditions are met:
  • A history of injury to the tongue resulting in impaired sensation or use of the tongue.
  • Visible open lesions, cold sores, abrasions, blisters, or rash on the tongue.
  • Oral surgery or dental work in the past 3 months or anticipated to occur for the duration of participation in the study (does not include routine dental health exams/cleanings).
  • Piercing on the tongue.
  • Known neuropathies of tongue or skin tactile system.
  • Unwilling or unable to adhere to all study requirements, including completion of the training period, evaluation tests and follow up visits.
  • Implanted electrical medical devices such as pacemakers.
  • Known allergies to nickel, gold or other components of stainless steel.
  • Patients who are 18 years and older or younger than 4.
  • Women who are pregnant or breast feeding will not be able to participate in this study (as indicated by a positive pregnancy test).
  • Children with neurodevelopmental disorders (e.g., autism, learning disabilities) or congenital brain malformations will be excluded from participation.
  • Cortical blindness from any cause.
  • Claustrophobia that would prevent functional neuroimaging (for those subjects undergoing neuroimaging only).
  • Obesity preventing placement in MRI scanner (for those subjects undergoing neuroimaging only).
  • Presence of any foreign metal in the body with the exception of dental fillings.
  • Implanted metallic or ferromagnetic objects (aneurysm clip, ear implant, IUD, shrapnel or metallic fragments in or on the body or eyes, neuro-stimulators, or other metal devices).

Trial locations and contacts

1 site in 1 country.

United States1 site
  • UPMC Eye Center

    Pittsburgh, Pennsylvania, 15213

Other trials in United States

About this study

The BrainPort vision device is a visual prosthetic designed for those who are blind. It enables perception of visual information using the tongue and camera system as a paired substitute for the eye. Visual information is collected from a video camera and translated into a gentle vibration that is presented to the subject on the tongue. With training users perceive shape, size, location and motion of objects in their environment. It is a functional, non-surgical device developed to demonstrate as an aid to the visually impaired.

The aim of this proposal is to evaluate a non-surgical visual prosthetic (BrainPort vision device) that enables the blind to appreciate their immediate surroundings and determine the way the brain interprets the information. Our goal is to determine if the device can be used in a pediatric population by measuring the subjects' improvement over baseline in any of the following areas: light detection, light localization, movement perception, and standardized object recognition tasks after use of the BrainPort.

Read the detailed description

Objective:

Our objective is to determine if the functional improvements seen in blind subjects using the BrainPort can be realized in a pediatric cohort.

Specific Aims:

The aim of this proposal is to evaluate a non-surgical visual prosthetic (BrainPort vision device) that enables the blind to appreciate their immediate surroundings and determine the way the brain interprets the information. Our main goal is to determine if the device can be used in a pediatric population by measuring the subjects' improvement over baseline in any of the following areas: light detection, light localization, movement perception, and standardized object recognition tasks after use of the BrainPort.

As a second aim, the investigators will use a multimodal MR scanning session to study the neurophysiological basis of sensory substitution in children. Under this aim the investigators will pursue two main objectives. First, the investigators will correlate the behavioral data with the imaging data in order to detect regions of the brain where structure and/or function are associated with successful use of sensory substitution devices. Second, the investigators will utilize these data along with previously collected adult data to model the effects of prior visual experience on visual cortex plasticity due to blindness.

Background:

The BrainPort vision device is a visual prosthetic designed for those who are blind. It enables perception of visual information using the tongue and camera system as a paired substitute for the eye. Visual information is collected from a video camera and translated into gentle electrical stimulation patterns on the surface of the tongue. With training, users perceive shape, size, location and motion of objects in their environment. It is a functional, non-surgical device developed to demonstrate as an aid to the visually impaired.

Tactile sensory systems have proven capable of carrying information to the brain that is usually acquired visually. Braille and the long cane have provided such information to blind persons for decades, and in the 1960's it was clearly demonstrated that tactile inputs could provide access to written print1 and visual images2. The main limitation to the development of practical vision substitution has been the inadequacy of brain-machine interfaces. Thirty-five years ago Paul Bach-y-Rita, MD wrote "That a successful sensory substitution system is not presently in use may not be due to limited functional capabilities of the brain; it may be due to the fact that an artificial receptor system has not yet been constructed to challenge the adaptive capacities of the human brain"3.

BrainPort Vision Device Since 1998, Wicab has focused on biomedical engineering research and development of commercial devices based on its proprietary BrainPort® technology4. The BrainPort vision device is a visual prosthetic designed for those who are blind.

Numerous previous studies support using the tongue as a sensory substitution channel2,3,5-8. Our and others' research has revealed that the brain can correctly interpret information from a sensory substitution device, even when the information is not presented in the same pathway as the natural sensory system. For example, the optical image actually received by the eye travels no farther than the retina, which converts the image into spatio-temporal patterns of action potentials along the optic nerve fibers. By analyzing these impulse patterns, the brain recreates the image. These impulses are not unique for vision. In fact, all sensory systems code information using the same 'language': neuronal action potentials. Using the vision example as a paradigm, sensory substitution requires only that action potentials be accurately entrained in the alternate sensory information channel. With training, the brain may learn to appropriately interpret information from the alternate channel and then to process that information much as it would data from the intact natural sense. Therefore, this technology benefits users by stimulating the tongue with usable information about their environment, which some users have described as resembling vision.

Although BrainPort technology stimulates the tongue through the electrode array, the stimulation is not at all painful; a BrainPort device emits only 11.85 µJ per pulse (regulatory limit for cutaneously electrical stimulating devices: 300 mJ). In fact, users often report the sensation as being like champagne bubbles effervescing on the tongue. Participants using BrainPort devices, whether for several hours each day over the course of a few weeks or for 20 minutes a day for up to one year, report no discomfort.

Little work has been done using imaging to study blind children. Werth and Seelos used fMRI to measure evoked activity in the visual cortex of children as evidence of visual function improvement following field training (Neurpsychologica. 2005. 43(14): 2011). However, to our knowledge, imaging of blind children to assess plasticity of the visual cortex at such a young age has not been done. In the short term, imaging of these subjects may improve our ability to screen for patients who would benefit from sensory substitution devices as well as to evaluate training paradigms. In the long term, understanding plasticity due to visual deprivation will be important not just for sensory substitution, but for all vision restoration strategies in order to identify subjects still capable of processing visual input. As the investigators attempt to model the effects of prior visual experience on plasticity in the visual cortex following blindness, children represent a unique and essential portion of the sample to tease apart the relative effects of blindness duration and early versus late acquisition.

The BrainPort device has been approved by the FDA since June of 2015.

Significance:

The BrainPort vision device is a visual prosthetic designed for those who are blind. It enables perception of visual information using the tongue and camera system as a paired substitute for the eye. Visual information is collected from a video camera and translated into gentle electrical stimulation patterns on the surface of the tongue. With training users perceive shape, size, location and motion of objects in their environment. It is a functional, non-surgical device developed to demonstrate as an aid to the visually impaired. The BrainPort vision device is the only new technology likely available in the near term to address safety and mobility issues resulting from blindness.

Our results have shown that the use of the BrainPort results in behavioral improvements as well as activation in visual cortical regions using fMRI and PET scans in adults. A trial which seeks to determine if functional abilities can also be improved in a pediatric cohort is justifiable for the following reasons:

  1. Neuroplasticity is highest in childhood, and the visually deprived brain is likely to be most receptive to alternative sensory stimulation in this age group.
  2. The BrainPort is non-invasive.
  3. Other than gene therapy for Leber's Congenital Amaurosis, there are no alternatives to restoring vision for the blind children at this time.
  4. The BrainPort already has CE Mark approval and pending FDA approval (final safety study documents submitted to the FDA August 2013), and should be available for purchase by 2014, at least in Europe and Canada. Whether the device could be useful in a pediatric population is an important clinical question.
  5. The relation of the anticipated benefit to the risk presented by the study is at least as favorable to the subjects as that provided by available alternative approaches (blind training).
Conditions
Blindness
Being tested
BrainPort V200 Device
Medical subject headings
Blindness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BrainPort V200 DeviceDevice

    To see if the device can be used in a pediatric population by measuring the subjects' improvement over baseline in any of the following areas: light detection, light localization, movement perception, and standardized object recognition tasks after use of the BrainPort.

Study groups in NCT03002597
Study groupRoleWhat they receive
Blind ChildrenExperimentalChildren between the ages of 4 and 17 who are blind (documented visual acuity of light perception or worse) in both eyes from an eye care provider.
Receives: Device: BrainPort V200 Device
Sighted ChildrenExperimentalChildren between the ages of 4 and 17 who are sighted in both eyes.
Receives: Device: BrainPort V200 Device

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluate BrainPort Device

    The efficacy endpoint for this study is a statistical analysis of subjects' improvement over baseline in any of the following areas: light detection, light localization, movement perception (BaGA testing), and standardized object recognition tasks after use of the BrainPort. The mean data reported is the average percentage that participants were able to successfully complete the tested tasks over the 5 visits.

    Measured: 5 visits over the course of approximately 2 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Dec 2016 (estimated)
  2. Study startJan 2014
  3. Primary completionJun 2021
  4. Study completionJun 2021

Why it stopped: Issue reaching target enrollement

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
9 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03002597
Sponsor's protocol ID
STUDY19080134
Status last verified
Jul 2023
First submitted
20 Dec 2016
Last updated
16 Aug 2023
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing BrainPort V200 Device in people with Blindness, run by Ellen Mitchell at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 37 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 16 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 16 Aug 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluate BrainPort Device (time frame: 5 visits over the course of approximately 2 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Aug 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in